Aurobindo Pharma has announced that it received final approval from the U.S. Food and Drug Administration (USFDA) to manufacture and market Glycerol Phenylbutyrate Oral Liquid at a concentration of 1.1 grams per ml. This product is bioequivalent and therapeutically equivalent to Ravicti, which is marketed by Horizon Therapeutics U.S. Holding LLC. The drug is indicated for the chronic management of patients with urea cycle disorders (UCDs) who cannot be managed through dietary protein restriction and amino acid supplementation alone. The product will be manufactured at Aurobindo's Unit-III facility and will be launched immediately. According to IQVIA MAT data, the estimated market size for Glycerol Phenylbutyrate Oral Liquid is $50.2 million for the 12 months ending February 2026. With this approval, Aurobindo Pharma's total Abbreviated New Drug Application (ANDA) approvals from the USFDA have reached 579, comprising 556 final approvals and 23 tentative approvals. Additionally, the company reported a 7.6% increase in consolidated net profit to ₹910.29 crore (approximately $110 million USD) on a 9% rise in net sales to ₹8,604.51 crore (approximately $1.04 billion USD) in Q3 FY26 compared to Q3 FY25. Following this announcement, Aurobindo's stock rose 0.09% to ₹1,387.30 on the Bombay Stock Exchange (BSE).